-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On August 16, the official website of NMPA showed that Novartis Ranibizumab's new indications for marketing application (acceptance number: JXSS2000038/44/45/46/47) were approved, and it is speculated to be used for the treatment of retinopathy of prematurity and diabetic retinopathy ( DR)
Retinopathy of prematurity is the main cause of blindness in premature infants.
Diabetic retinopathy (DR) is a series of typical lesions caused by retinal microvascular damage caused by diabetes.
PDR is a more serious type of vision-threatening diabetic retinopathy (DR)
At first, DR may have no symptoms or cause only a slight loss of vision, but over time, DR will progress from non-proliferative DR (NPDR) to vision-threatening PDR
Ranibizumab is a VEGF (vascular endothelial growth factor) inhibitor developed by Roche, with a small molecular weight of only 48kD
In 2003, Roche and Novartis reached an agreement.
According to the NextPharma database of Medicine Rubik's Cube, ranibizumab has been approved for 6 major indications worldwide, namely: wet age-related macular degeneration; diabetic retinopathy; macular edema secondary to retinal vein occlusion; myopic choroidal neovascularization ; Retinopathy of prematurity; Diabetic macular edema
In China, ranibizumab has been approved for 4 indications, namely: wet age-related macular degeneration (wAMD); diabetic macular edema (DME); secondary to retinal vein occlusion (RVO) (branch retinal vein occlusion) (BRVO) or central retinal vein occlusion (CRVO)) vision damage caused by macular edema; treatment of vision damage caused by choroidal neovascularization (CNV, that is, CNV secondary to pathological myopia (PM) and other causes)
Since the launch of ranibizumab in 2006, global sales have basically maintained at US$3 billion
Novartis Sales
Roche sales
It is worth noting that the global patent of ranibizumab will expire in recent years, and many domestic companies are deploying Me-too drugs or biosimilar drugs, and Novartis' new-generation ophthalmic drug Beovu is in the phase III clinical trial stage in China
